Eli Lilly and Company $LLY Shares Purchased by Schnieders Capital Management LLC

Key Points

• Schnieders Capital Management LLC increased its stake in Eli Lilly by 16.7% during Q2, now holding nearly 8,000 shares valued at approximately $6.23 million.
• Various institutional investors, including PNC Financial Services and Vanguard Group, have significantly increased their holdings in Eli Lilly, indicating strong confidence in the company.
• Despite a drop in stock price of 1.9%, Eli Lilly reported a Q2 earnings per share of $6.31, surpassing analysts' expectations, with revenue rising 37.6% year-over-year.

Schnieders Capital Management LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,993 shares of the company's stock after buying an additional 1,141 shares during the quarter. Eli Lilly and Company comprises 1.1% of Schnieders Capital Management LLC's investment portfolio, making the stock its 25th biggest holding. Schnieders Capital Management LLC's holdings in Eli Lilly and Company were worth $6,231,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC purchased a new position in shares of Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Cohen Investment Advisors LLC increased its position in Eli Lilly and Company by 7,975.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after acquiring an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock valued at $1,154,508,000 after acquiring an additional 765,010 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LLY shares. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. Erste Group Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Tuesday, October 14th. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $939.12.

Eli Lilly and Company Stock Down 1.9%

LLY stock opened at $803.53 on Monday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company's 50-day moving average price is $753.09 and its 200 day moving average price is $765.70. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a market cap of $760.51 billion, a P/E ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In related news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.